Drug Profile
Insulin glargine biosimilar - Wockhardt
Alternative Names: Glaritus; Glaritus DispoPen; Glaritus Pen Royale; GlaritusCartLatest Information Update: 30 Oct 2021
Price :
$50
*
At a glance
- Originator Wockhardt
- Class Antihyperglycaemics; Insulins; Pancreatic hormones
- Mechanism of Action Insulin receptor agonists; Ornithine decarboxylase antizyme stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Type 1 diabetes mellitus; Type 2 diabetes mellitus
Most Recent Events
- 03 Oct 2019 Wockhardt withdrew a phase III trial prior to enrolment for type 1 diabetes mellitus in USA and India due to business strategy decision (SC) (NCT01352663)
- 16 Jul 2016 No recent reports of development identified for phase-I development in Type-1 diabetes mellitus in USA (SC, Injection)
- 26 Aug 2013 Launched for Type-1 diabetes mellitus in Nepal, Sri Lanka and Tanzania (SC) after August 2013